A change from Heparin to Citrate as Anticoagulation for CRRT in SWB Critical Care Sandwell and West Birmingham

Authors: Fahad Zahid, Roshni Baid, Deepak Sharma

Introduction

- Acute Kidney Injury (AKI) is a common condition that worsens mortality and morbidity in critically ill patients. It also comes with a heavy cost to the treating units.
- The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend that uniformity in how we manage these patients by standard protocols will reduce variations, improve outcomes, and thereby reduce costs.¹
- There are benefits to promoting the use of citrate as regional anticoagulation against heparin.²
- Our unit changed from heparin to citrate for regional anticoagulation in 2021-2022. This allowed us to conduct a study to find out the benefits and cost-effectiveness of this change.



Pre-citrate

Citrate

NHS Trust

Purpose

- Primary questions we were trying to answer were comparison of Heparin and Citrate Groups in terms of:
- 1. Number of circuits used?

4.

- 2. Duration of each circuit use?
- 3. Frequency of Blood lost with the circuit (unable to wash back the filter)
 - Number of Blood transfusion per patient between 2 groups?

Methods and Analysis

- We collected retrospective data from the hospital's online system for four months on heparin and citrate use.
- The data included the number of circuits used, circuit life, and requirements for packed red blood cells (pRBC) transfusions.
- We wanted to see if using citrate would reduce costs by using fewer circuits or by requiring fewer transfusions.





**

- 3,941 hours. In the citrate group, 53 patients required CRRT for a total of 10,516 hours.
- The mean duration of CRRT per patient was 101 hours in the heparin group and 198 hours in the citrate group. This difference was statistically significant, with a p-value of 0.03.
- The citrate group's mean filter life was also noticeably longer, at 67 hours as opposed to 24 hours in the heparin group. The number of pRBC transfusions required was also lower in
- the citrate group, at 0.38 units per day compared to 0.5 units per day in the heparin group.

References:

Work group membership. Kidney International Supplements. 2012;2(1):2. doi:10.1038/kisup.2012.2
Oudemans-van Straaten HM, Kellum JA, Bellomo R. Clinical review: Anticoagulation for continuous renal replacement therapy - heparin or citrate? Critical Care 2011; 15: 202

- with systemic heparinization, with a cost saving of approximately £35,000 per year, in addition to previously reported patient benefits.
- There is a non-significant trend towards a reduction in blood transfusion requirements, representing an annual cost saving of $\pounds 6,400$.
- The time on dialysis was significantly higher on citrate filter, the cause of which was not the objective of this project but will be looked at upcoming projects.

Acknowledgements: Afelemo Orilade, Ahmad Daebis, Sophie Randal